Creabilis Raises €15M in Series B Fundraising Round
Creabilis SA has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s first-in-class treatments, including its lead product CT327 to the end of phase II.
CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis’ Low Systemic Exposure (LSE) technology. Positive efficacy of CT327 has been seen in two Phase IIa studies, in both psoriasis and atopic dermatitis, in which CT327 was well tolerated and demonstrated a good safety profile. CT327 is also in development for the treatment of pain, with proof-of-concept trials currently underway.
The company’s pipeline also includes CT637, a new approach to the treatment of significant inflammatory and autoimmune conditions and CT340, a potent TrkA kinase inhibitor that has therapeutic potential in a broad range of inflammatory conditions. CT637 and CT340 are anticipated to reach Investigational New Drug application (IND) stage of development in early 2012.
Dr Eliot Forster CEO of Creabilis said: “This new funding reflects the medical importance and significant commercial potential of our drugs pipeline. In Abbott Biotech Ventures, we have added another leading life science investor into the Company. Their involvement, and the ongoing support of our existing investors, demonstrates their confidence in the Company and in our ability to drive our projects forward.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Zeiss strenghtens in-house quality and production management
Vanderbilt researchers identify potent antibodies against HIV - Structure-based approach could lead to first effective vaccine
Blood-brain barrier company to-BBB moves into commercialization mode with new CEO Willem van Weperen
Oviposition behaviour of pest insects keeps Bt-cotton durably resistant - Moths behave like Darwin’s finches

Tumour growth roadmap developed
Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines

Excess weight, obesity more deadly than previously believed - One in six U.S. adult deaths are related to country's 'obesogenic' environment, study suggests

New technology could aid stem cell transplantation research

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis
Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
